Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy

NCT02758717 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT02758717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02758717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 13, 2016
Completion date
September 13, 2025
Enrollment
46 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ib hodgkin lymphoma, ann arbor stage ii hodgkin lymphoma, ann arbor stage iia hodgkin lymphoma, ann arbor stage iib hodgkin lymphoma, ann arbor stage iii hodgkin lymphoma, ann arbor stage iiia hodgkin lymphoma, ann arbor stage iiib hodgkin lymphoma, ann arbor stage iv hodgkin lymphoma, ann arbor stage iva hodgkin lymphoma, ann arbor stage ivb hodgkin lymphoma, classic hodgkin lymphoma